Search

Your search keyword '"Wallace, Daniel"' showing total 2,397 results
Start Over Author "Wallace, Daniel"
2,397 results on '"Wallace, Daniel"'

102. Contributors

Author

Ambinder, Richard F., primary, Baer, Alan N., additional, Basiaga, Matthew L., additional, Briggs, Ianna, additional, Bunya, Vatinee Y., additional, Carsons, Steven, additional, Chakrabarty, Eliza F., additional, Fox, Robert I., additional, Fox, Carla M., additional, George, Michael D., additional, Goldberg, Elisabeth, additional, Gonzales, John A., additional, Hammitt, Katherine M., additional, Johr, Chadwick R., additional, Kilar, Adriane, additional, Lawrence–Ford, Theresa, additional, Leung, Yiu Tak, additional, Lewis, Janet, additional, Lieberman, Scott M., additional, Mahajan, Shalini, additional, Mandel, Steven, additional, Massaro-Giordano, Mina, additional, Mongroo, Rana, additional, Noaiseh, Ghaith, additional, Orlin, Stephen E., additional, Papas, Athena, additional, Pavlakis, Pantelis P., additional, Sandorfi, Nora, additional, Scofield, R. Hal, additional, Singh, Mabi L., additional, Stern, Sara M., additional, Sulewski, Michael E., additional, Taylor, Steven, additional, Varadhachary, Arun, additional, Varghese, Bivin, additional, Vivino, Frederick B., additional, Wallace, Daniel J., additional, and Younger, David S., additional

Published
2020
Full Text
View/download PDF

106. A promising approach to targeting type 1 IFN in systemic lupus erythematosus

Author

Chaichian, Yashaar, Wallace, Daniel J., and Weisman, Michael H.

Subjects
Interferon -- Research, Systemic lupus erythematosus -- Care and treatment -- Research, Cellular signal transduction -- Research, Skin, Antigens, Lupus erythematosus, Belimumab, B cells, Clinical trials, Lupus, Ustekinumab, Health care industry
Abstract

Despite advances in understanding systemic lupus erythematosus (SLE) pathogenesis, most clinical trials of new targeted therapies have been met with disappointment. The type I IFN pathway is believed to play an important role in SLE, and the proposed involvement of this pathway helps explain the frustration behind the failure at targeting either IFN-[alpha] or the type 1 IFN receptor itself. In this issue of the JCI, Furie et al. report on an intriguing phase 1b study that demonstrates an approach for inhibiting this pathway in the skin using an mAB (BIIB059) that targets the blood DC antigen 2 (BDCA-2) receptor on plasmacytoid DCs (pDCs). BIIB059 decreased IFN expression and improved cutaneous lupus disease activity, with a favorable safety profile. Whether or not this strategy will be effective in managing SLE in other organs remains unanswered. However, these results suggest that closing the door on targeting the type 1 IFN pathway in SLE may be premature and highlight the emerging question of whether an organ-specific approach toward lupus trials and treatment should be the wave of the future., SLE treatment--unmet need and limitations of previous clinical trials Disease remission remains an elusive goal for many patients with systemic lupus erythematosus (SLE) (1), even as mortality rates for SLE [...]

Published
2019
Full Text
View/download PDF

107. Non-lymphoma hematological malignancies in systemic lupus erythematosus.

Author

Lu, Mary, Bernatsky, Sasha, Ramsey-Goldman, Rosalind, Petri, Michelle, Manzi, Susan, Urowitz, Murray B, Gladman, Dafna, Fortin, Paul R, Ginzler, Ellen M, Yelin, Edward, Bae, Sang-Cheol, Wallace, Daniel J, Jacobsen, Soren, Dooley, Mary Anne, Peschken, Christine A, Alarcón, Graciela S, Nived, Ola, Gottesman, Lena, Criswell, Lindsey A, Sturfelt, Gunnar, Dreyer, Lene, Lee, Jennifer L, and Clarke, Ann E

Subjects
Humans, Hematologic Neoplasms, Lupus Erythematosus, Systemic, Incidence, Cohort Studies, Adult, Aged, Middle Aged, Female, Male, Pediatric Cancer, Clinical Research, Rare Diseases, Lymphoma, Hematology, Lupus, Cancer, Orphan Drug, Pediatric, Childhood Leukemia, 2.1 Biological and endogenous factors, Aetiology, Systemic lupus erythematosus, Malignancy, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

ObjectiveTo describe non-lymphoma hematological malignancies in systemic lupus erythematosus (SLE).MethodsA large SLE cohort was linked to cancer registries. We examined the types of non-lymphoma hematological cancers.ResultsIn 16,409 patients, 115 hematological cancers [including myelodysplastic syndrome (MDS)] occurred. Among these, 33 were non-lymphoma. Of the 33 non-lymphoma cases, 13 were of lymphoid lineage: multiple myeloma (n = 5), plasmacytoma (n = 3), B cell chronic lymphocytic leukemia (B-CLL; n = 3), precursor cell lymphoblastic leukemia (n = 1) and unspecified lymphoid leukemia (n = 1). The remaining 20 cases were of myeloid lineage: MDS (n = 7), acute myeloid leukemia (AML; n = 7), chronic myeloid leukemia (CML; n = 2) and 4 unspecified leukemias. Most of these malignancies occurred in female Caucasians, except for plasma cell neoplasms (4/5 multiple myeloma and 1/3 plasmacytoma cases occurred in blacks).ConclusionsIn this large SLE cohort, the most common non-lymphoma hematological malignancies were myeloid types (MDS and AML). This is in contrast to the general population, where lymphoid types are 1.7 times more common than myeloid non-lymphoma hematological malignancies. Most (80%) multiple myeloma cases occurred in blacks; this requires further investigation.

Published
2013

109. THE BOOK THAT MADE DANIEL WALLACE A DIFFERENT WRITER: The acclaimed novelist wondered how hard writing a memoir could really be. As it turned out: very, very, very hard

Author

Wallace, Daniel

Subjects
This Isn't Going to End Well (Autobiography) -- Personal narratives -- Authorship, Creative writing -- Methods -- Personal narratives, Publishing industry
Abstract

* This Isn't Going to End Well Algonquin, $28, 9781643752105 Memoir The books I've written so far began almost accidentally. Not the day-to-day, year-to-year accumulation of words--no accidents there. But [...]

Published
2023

110. Baricitinib for systemic lupus erythematosus

Author

Morand, Eric F., Vital, Edward M., Petri, Michelle, van Vollenhoven, Ronald, Wallace, Daniel J., Mosca, Marta, Furie, Richard A., Silk, Maria E., Dickson, Christina L., Meszaros, Gabriella, Jia, Bochao, Crowe, Brenda, de la Torre, Inmaculada, Dörner, Thomas, Rheumatology, AII - Inflammatory diseases, Clinical Immunology and Rheumatology, and AMS - Musculoskeletal Health

Subjects
General Medicine
Abstract

Background: Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase 2 study in patients with systemic lupus erythematosus (SLE), baricitinib 4 mg significantly improved SLE disease activity compared with placebo. The objective of this trial was to evaluate the efficacy and safety of baricitinib in patients with active SLE in a 52-week phase 3 study. Methods: In a multicentre, double-blind, randomised, placebo-controlled, parallel-group, phase 3 study, SLE-BRAVE-I, patients (aged ≥18 years) with active SLE receiving stable background therapy were randomly assigned 1:1:1 to baricitinib 4 mg, 2 mg, or placebo once daily for 52 weeks with standard of care. Glucocorticoid tapering was encouraged but not required per protocol. The primary endpoint was the proportion of patients reaching an SLE Responder Index (SRI)-4 response at week 52 in the baricitinib 4 mg treatment group compared with placebo. The primary endpoint was assessed by logistic regression analysis with baseline disease activity, baseline corticosteroid dose, region, and treatment group in the model. Efficacy analyses were done on a modified intention-to-treat population, comprising all participants who were randomly assigned and received at least one dose of investigational product. Safety analyses were done on all randomly assigned participants who received at least one dose of investigational product and who did not discontinue from the study for the reason of lost to follow-up at the first post-baseline visit. This study is registered with ClinicalTrials.gov, NCT03616912. Findings: 760 participants were randomly assigned and received at least one dose of baricitinib 4 mg (n=252), baricitinib 2 mg (n=255), or placebo (n=253). A significantly greater proportion of participants who received baricitinib 4 mg (142 [57%]; odds ratio 1·57 [95% CI 1·09 to 2·27]; difference with placebo 10·8 [2·0 to 19·6]; p=0·016), but not baricitinib 2 mg (126 [50%]; 1·14 [0·79 to 1·65]; 3·9 [–4·9 to 12·6]; p=0·47), reached SRI-4 response compared with placebo (116 [46%]). There were no significant differences between the proportions of participants in either baricitinib group reaching any of the major secondary endpoints compared with placebo, including glucocorticoid tapering and time to first severe flare. 26 (10%) participants receiving baricitinib 4 mg had serious adverse events, 24 (9%) participants receiving baricitinib 2 mg, and 18 (7%) participants receiving placebo. The safety profile of baricitinib in participants with SLE was consistent with the known baricitinib safety profile. Interpretation: The primary endpoint in this study was met for the 4 mg baricitinib group. However, key secondary endpoints were not. No new safety signals were observed. Funding: Eli Lilly and Company.

Published
2023
Full Text
View/download PDF

111. New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus

Author

Wang, Fang-Fang, Zhu, Li-An, Zou, Yu-Qiong, Zheng, Hui, Wilson, Alisa, Yang, Cheng-De, Shen, Nan, Wallace, Daniel J, Weisman, Michael H, Chen, Shun-Le, and Lu, Liang-Jing

Abstract

Abstract Introduction Glucocorticoid (GC) therapy remains important in improving the prognosis of patients with systemic lupus erythematosus (SLE). However, some patients do not achieve an effective response with GC treatment, creating an obstacle to the remission of SLE. Identification of the underlying mechanisms responsible for steroid resistance can be significant. Macrophage migration inhibitory factor (MIF) arouses our interest because of its reciprocal relationship with GCs. In the present study, we investigated for the first time whether MIF correlated with steroid resistance in SLE and explored potential mechanisms of action. Methods Sixty-two patients with SLE (40 steroid sensitive and 22 steroid resistant) and 21 normal controls were recruited. Serum levels of MIF were measured by ELISA. Cytosolic MIF and IκB expression in peripheral blood mononuclear cells (PBMCs) were determined by western blotting. The electrophoretic mobility shift assay was assessed by NF-κB in nuclear aliquots. Gene silencing was applied to reduce expression of MIF in PBMCs in steroid-resistant patients. PBMCs obtained from steroid-sensitive patients were treated with recombinant human MIF of different concentrations. Results MIF levels in serum and PBMCs were higher in steroid-resistant patients compared with steroid-sensitive patients and controls. In contrast to the steroid-sensitive group, NF-κB levels were significantly higher and IκB levels lower in steroid-resistant patients. After MIF gene silencing, IκB levels in cells from steroid-resistant patients were increased. In steroid-sensitive patients, a decrease in IκB levels and an increase in NF-κB expression from baseline were detected in PBMCs treated with a higher concentration of recombinant human MIF. Treatment with recombinant human MIF did not regulate expression of IκB and NF-κB in PBMCs from patients treated with an anti-MIF monoclonal antibody. Conclusions Our results indicated that MIF may play a role in the formation of steroid resistance in SLE by affecting the NF-κB/IκB signaling cascade. As a regulator of glucocorticoid sensitivity, MIF may be a potential target for steroid sparing.

Published
2012

112. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids

Author

McMahon, Maureen, Skaggs, Brian J, Sahakian, Lori, Grossman, Jennifer, FitzGerald, John, Ragavendra, Nagesh, Charles-Schoeman, Christina, Chernishof, Marissa, Gorn, Alan, Witztum, Joseph L, Wong, Weng Kee, Weisman, Michael, Wallace, Daniel J, La Cava, Antonio, and Hahn, Bevra H

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Prevention, Autoimmune Disease, Atherosclerosis, Lupus, Clinical Research, Cardiovascular, Aetiology, 2.1 Biological and endogenous factors, Inflammatory and immune system, Adipokines, Adult, Biomarkers, Body Mass Index, Carotid Artery, Common, Epidemiologic Methods, Female, Humans, Inflammation Mediators, Leptin, Lipids, Lupus Erythematosus, Systemic, Middle Aged, Oxidation-Reduction, Ultrasonography, Clinical Sciences, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

BackgroundPatients with systemic lupus erythematosus (SLE) are at increased risk of atherosclerosis, even after accounting for traditional risk factors. High levels of leptin and low levels of adiponectin are associated with both atherosclerosis and immunomodulatory functions in the general population.ObjectiveTo examine the association between these adipokines and subclinical atherosclerosis in SLE, and also with other known inflammatory biomarkers of atherosclerosis.MethodsCarotid ultrasonography was performed in 250 women with SLE and 122 controls. Plasma leptin and adiponectin levels were measured. Lipoprotein a (Lp(a)), oxidised phospholipids on apoB100 (OxPL/apoB100), paraoxonase, apoA-1 and inflammatory high-density lipoprotein (HDL) function were also assessed.ResultsLeptin levels were significantly higher in patients with SLE than in controls (23.7±28.0 vs 13.3±12.9 ng/ml, p

Published
2011

113. Advances in drug therapy for systemic lupus erythematosus

Author

Wallace, Daniel J

Abstract

Abstract Systemic lupus erythematosus (SLE) is an autoimmune disorder that afflicts 500,000 people in the United States. There has not been a new SLE drug approved in the United States since 1958. However, a guidance document issued by the Food and Drug Administration in 2005 provided a roadmap for investigators which spawned numerous ongoing clinical trials. Among these, Belimumab, a monoclonal antibody to soluble B lymphocyte stimulator, met its primary endpoints in two large trials and will probably obtain FDA approval soon. Other promising agents targeting a variety of mechanisms of action are currently in development. This minireview highlights the latest therapies under investigation in SLE and gives an overview of the pathways that are specifically being targeted.

Published
2010

115. Reduced left ventricular function on cardiac MRI of SLE patients correlates with measures of disease activity and inflammation

Author

Hagiwara, Audrey M., primary, Montano, Erica, additional, Tumurkhuu, Gantseg, additional, Bose, Moumita, additional, Bernardo, Marianne, additional, Berman, Daniel S., additional, Cook Wiens, Galen, additional, Nelson, Michael D., additional, Wallace, Daniel, additional, Wei, Janet, additional, Ishimori, Mariko, additional, Bairey Merz, C. Noel, additional, and Jefferies, Caroline, additional

Published
2023
Full Text
View/download PDF

116. A Novel Saliva-Based miRNA Profile to Diagnose and Predict Oral Cancer

Author

Punyadeera, Chamindie, primary, Balakittnen, Jaikrishna, additional, Weeramange, Chameera Ekanayake, additional, Wallace, Daniel F., additional, Duijf, Pascal H.G., additional, Cristino, Alexandre S., additional, Hartel, Gunter, additional, Barrero, Roberto A., additional, Taheri, Touraj, additional, Kenny, Liz, additional, Vasani, Sarju, additional, Batstone, Martin, additional, and Breik, Omar, additional

Published
2023
Full Text
View/download PDF

118. LSO-083 ‘Systemic lupus erythematosus women with lupus nephritis in pregnancy therapeutic challenge (SWITCH)’: the systemic lupus international collaborating clinics experience

Author

Lee, Joo-Young (Esther), primary, Mendel, Arielle, additional, Askanase, Anca, additional, Bae, Sang-Cheol, additional, Buyon, Jill, additional, Clarke, Ann E, additional, Costedoat-Chalumeau, Nathalie, additional, Fortin, Paul R, additional, Gladman, Dafna, additional, Ramsey-Goldman, Rosalind, additional, Hanly, John G, additional, Inanç, Murat, additional, Isenberg, David, additional, Mak, Anselm, additional, Mosca, Marta, additional, Petri, Michelle, additional, Rahman, Anisur, additional, Sanchez-Guerrero, Jorge, additional, Urowitz, Murray, additional, Wallace, Daniel, additional, Bernatsky, Sasha, additional, and Vinet, Évelyne, additional

Published
2023
Full Text
View/download PDF

119. LO-024 Association between severe non-adherence to hydroxychloroquine and SLE flares, damage, and mortality in 660 patients from the SLICC inception cohort

Author

Nguyen, Yann, primary, Blanchet, Benoît, additional, Urowitz, Murray B, additional, Hanly, John G, additional, Gordon, Caroline, additional, Bae, Sang-Cheol, additional, Romero-Diaz, Juanita, additional, Sanchez-Guerrero, Jorge, additional, Clarke, Ann E, additional, Bernatsky, Sasha, additional, Wallace, Daniel J, additional, Isenberg, David A, additional, Rahman, Anisur, additional, Merrill, Joan T, additional, Fortin, Paul R, additional, Gladman, Dafna D, additional, Bruce, Ian N, additional, Petri, Michelle, additional, Ginzler, Ellen M, additional, Dooley, Mary Anne, additional, Ramsey-Goldman, Rosalind, additional, Manzi, Susan, additional, Jönsen, Andreas, additional, Alarcón, Graciela S, additional, Vollenhoven, Ronald FVan, additional, Aranow, Cynthia, additional, Guern, Véronique Le, additional, Mackay, Meggan, additional, Ruiz-Irastorza, Guillermo, additional, Lin, Sam, additional, Inanc, Murat, additional, Kalunian, Kenneth C, additional, Jacobsen, Søren, additional, Peschken, Christine A, additional, Kamen, Diane L, additional, Askanase, Anca, additional, Buyon, Jill, additional, and Costedoat-Chalumeau, Nathalie, additional

Published
2023
Full Text
View/download PDF

120. List of Contributors

Author

Atisha-Fregoso, Yemil, primary, Avina-Zubieta, J. Antonio, additional, Barone, Francesca, additional, Benedek, Thomas G., additional, Ben-Zvi, Ayal, additional, Bernatsky, Sasha, additional, Boackle, Susan A., additional, Bootsma, Hendrika, additional, Bourn, Rebecka L., additional, Bowman, Simon J., additional, Bruce, Ian N., additional, Buyon, Jill P., additional, Carteron, Nancy L., additional, Cashman, Kevin S., additional, Chakravarty, Eliza F., additional, Chen, Sarah K., additional, Chin, Yuting, additional, Chong, Benjamin F., additional, Clarke, Ann E., additional, Cohen, Hannah, additional, Costenbader, Karen H., additional, Crispín, José C., additional, Crow, Mary K., additional, Dall'Era, Maria, additional, de Leeuw, Karina, additional, Deng, Yun, additional, Dey-Rao, Rama, additional, Diamond, Betty, additional, Dörner, Thomas, additional, Drenkard, Cristina, additional, Dumusc, Alexandre, additional, Durcan, Laura, additional, Dvorkina, Olga, additional, Egiziano, Giordano, additional, Elkon, Keith B., additional, Esdaile, John M., additional, Fisher, Benjamin A., additional, Fox, Carla M., additional, Fox, Robert I., additional, Friedman, Deborah M., additional, Fu, Shu Man, additional, Gaskin, Felicia, additional, Giles, Ian, additional, Ginzler, Ellen M., additional, Hahn, Bevra Hannahs, additional, Hanly, John G., additional, Hansen, James E., additional, Hiepe, Falk, additional, Hinojosa-Azaola, Andrea, additional, Hoyer, Bimba, additional, Humrich, Jens Y., additional, Ioannou, Yiannis, additional, Isenberg, David, additional, Ishimori, Mariko L., additional, Izmirly, Peter M., additional, James, Judith A., additional, Jefferies, Caroline A., additional, Jenks, Scott A., additional, Jolly, Meenakshi, additional, Jorge, April M., additional, Kallenberg, Cees G.M., additional, Kamen, Diane L., additional, Kaplan, Mariana J., additional, Karpouzas, George A., additional, Kimoto, Maryann, additional, Kirou, Kyriakos A., additional, Kono, Dwight H., additional, Kroese, Frans G.M., additional, Cava, Antonio La, additional, Lee, Christine H., additional, Lehman, Thomas J.A., additional, Lim, Lyndell L., additional, Lim, S. Sam, additional, Litvin, Irina, additional, Liu, Yudong, additional, Lood, Christian, additional, Manzi, Susan, additional, Means, Terry K., additional, Mejia-Vilet, Juan M., additional, Miliaresis, Christa, additional, Morand, Eric, additional, Morel, Laurence, additional, Nataraja, Champa, additional, Navarra, Sandra V., additional, Nayar, Saba, additional, Niewold, Timothy B., additional, Nowling, Tamara M., additional, Nuruzzaman, Farzana, additional, Oates, Jim C., additional, Oberst, Andrew, additional, Olsen, Nancy J., additional, Parker, Ben, additional, Petri, Michelle, additional, Phoon, Colin K.L., additional, Pisetsky, David S., additional, Putterman, Chaim, additional, Quismorio, Anne V., additional, Quismorio, Francisco P., additional, Rahman, Anisur, additional, Richardson, Bruce C., additional, Riemekasten, Gabriela, additional, Rosenbaum, James T., additional, Rovin, Brad H., additional, Sánchez-Guerrero, Jorge, additional, Sanz, Ignacio, additional, Sammaritano, Lisa R., additional, Sequeira, Winston, additional, Sharma, Tarun S., additional, Shen, Nan, additional, Sibley, Cailin, additional, Sinha, Animesh A., additional, Stevens, Brandi E., additional, Stock, Ariel D., additional, Suárez-Fueyo, Abel, additional, Sung, Sun-Sang J., additional, Taber, Sarah F., additional, Tang, Yuanjia, additional, Thibau, Isabelle J.C., additional, Torralba, Tito P., additional, Touma, Zahi, additional, Tsao, Betty P., additional, Tsokos, George C., additional, Urowitz, Murray B., additional, Venuturupalli, Swamy, additional, Vissink, Arjan, additional, Wallace, Daniel J., additional, Wang, Hongyang, additional, Ward, Michael M., additional, Weinberg, Stacy, additional, Werth, Victoria P., additional, West, Sterling G., additional, Xion, Le, additional, Yazdany, Jinoos, additional, Yelin, Edward, additional, Yu, Xiang, additional, and Zou, Yong-Rui, additional

Published
2019
Full Text
View/download PDF

121. Preface

Author

Wallace, Daniel J, primary and Hahn, Bevra Hannahs, additional

Published
2019
Full Text
View/download PDF

125. Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic Challenge (SWITCH): The Systemic Lupus International Collaborating Clinics experience

Author

Lee, Joo-Young E, primary, Mendel, Arielle, additional, Askanase, Anca, additional, Bae, Sang-Cheol, additional, Buyon, Jill P, additional, Clarke, Ann Elaine, additional, Costedoat-Chalumeau, Nathalie, additional, Fortin, Paul R, additional, Gladman, Dafna D, additional, Ramsey-Goldman, Rosalind, additional, Hanly, John G, additional, Inanç, Murat, additional, Isenberg, David Alan, additional, Mak, Anselm, additional, Mosca, Marta, additional, Petri, Michelle, additional, Rahman, Anisur, additional, Sanchez-Guerrero, Jorge, additional, Urowitz, Murray, additional, Wallace, Daniel J, additional, Bernatsky, Sasha, additional, and Vinet, Évelyne, additional

Published
2023
Full Text
View/download PDF

126. Socioeconomic Status, Reserve Capacity, and Depressive Symptoms Predict Pain in Rheumatoid Arthritis: An Examination of the Reserve Capacity Model

Author

Azizoddin, Desiree, primary, Olmstead, Richard, additional, Anderson, Kris-Ann, additional, Hirz, Alanna E., additional, Irwin, Michael R., additional, Gholizadeh, Shadi, additional, Weisman, Michael, additional, Ishimori, Mariko, additional, Wallace, Daniel, additional, and Nicassio, Perry, additional

Published
2023
Full Text
View/download PDF

127. Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling

Author

Clarke, Ann E., Hanly, John G., Urowitz, Murray B., St. Pierre, Yvan, Gordon, Caroline, Bae, Sang-Cheol, Romero-Diaz, Juanita, Sanchez-Guerrero, Jorge, Bernatsky, Sasha, Wallace, Daniel J., Isenberg, David A., Rahman, Anisur, Merrill, Joan T., Fortin, Paul R., Gladman, Dafna D., Bruce, Ian N., Petri, Michelle, Ginzler, Ellen M., Dooley, Mary Anne, Ramsey-Goldman, Rosalind, Manzi, Susan, Jönsen, Andreas, Alarcón, Graciela S., Van Vollenhoven, Ronald F., Aranow, Cynthia, Mackay, Meggan, Ruiz-Irastorza, Guillermo, Lim, S. Sam, Inanc, Murat, Kalunian, Kenneth C., Jacobsen, Soren, Peschken, Christine A., Kamen, Diane L., Askanase, Anca, Farewell, Vernon, Clarke, Ann E., Hanly, John G., Urowitz, Murray B., St. Pierre, Yvan, Gordon, Caroline, Bae, Sang-Cheol, Romero-Diaz, Juanita, Sanchez-Guerrero, Jorge, Bernatsky, Sasha, Wallace, Daniel J., Isenberg, David A., Rahman, Anisur, Merrill, Joan T., Fortin, Paul R., Gladman, Dafna D., Bruce, Ian N., Petri, Michelle, Ginzler, Ellen M., Dooley, Mary Anne, Ramsey-Goldman, Rosalind, Manzi, Susan, Jönsen, Andreas, Alarcón, Graciela S., Van Vollenhoven, Ronald F., Aranow, Cynthia, Mackay, Meggan, Ruiz-Irastorza, Guillermo, Lim, S. Sam, Inanc, Murat, Kalunian, Kenneth C., Jacobsen, Soren, Peschken, Christine A., Kamen, Diane L., Askanase, Anca, and Farewell, Vernon

Abstract

Objective To estimate direct and indirect costs associated with neuropsychiatric (NP) events in the Systemic Lupus International Collaborating Clinics inception cohort. Methods NP events were documented annually using American College of Rheumatology definitions for NP events and attributed to systemic lupus erythematosus (SLE) or non-SLE causes. Patients were stratified into 1 of 3 NP states (no, resolved, or new/ongoing NP event). Change in NP status was characterized by interstate transition rates using multistate modeling. Annual direct costs and indirect costs were based on health care use and impaired productivity over the preceding year. Annual costs associated with NP states and NP events were calculated by averaging all observations in each state and adjusted through random-effects regressions. Five- and 10-year costs for NP states were predicted by multiplying adjusted annual costs per state by expected state duration, forecasted using multistate modeling. Results A total of 1,697 patients (49% White race/ethnicity) were followed for a mean of 9.6 years. NP events (n = 1,971) occurred in 956 patients, 32% attributed to SLE. For SLE and non-SLE NP events, predicted annual, 5-, and 10-year direct costs and indirect costs were higher in new/ongoing versus no events. Direct costs were 1.5-fold higher and indirect costs 1.3-fold higher in new/ongoing versus no events. Indirect costs exceeded direct costs 3.0 to 5.2 fold. Among frequent SLE NP events, new/ongoing seizure disorder and cerebrovascular disease accounted for the largest increases in annual direct costs. For non-SLE NP events, new/ongoing polyneuropathy accounted for the largest increase in annual direct costs, and new/ongoing headache and mood disorder for the largest increases in indirect costs. Conclusion Patients with new/ongoing SLE or non-SLE NP events incurred higher direct and indirect costs., Objective: To estimate direct and indirect costs associated with neuropsychiatric (NP) events in the Systemic Lupus International Collaborating Clinics inception cohort. Methods: NP events were documented annually using American College of Rheumatology definitions for NP events and attributed to systemic lupus erythematosus (SLE) or non-SLE causes. Patients were stratified into 1 of 3 NP states (no, resolved, or new/ongoing NP event). Change in NP status was characterized by interstate transition rates using multistate modeling. Annual direct costs and indirect costs were based on health care use and impaired productivity over the preceding year. Annual costs associated with NP states and NP events were calculated by averaging all observations in each state and adjusted through random-effects regressions. Five- and 10-year costs for NP states were predicted by multiplying adjusted annual costs per state by expected state duration, forecasted using multistate modeling. Results: A total of 1,697 patients (49% White race/ethnicity) were followed for a mean of 9.6 years. NP events (n = 1,971) occurred in 956 patients, 32% attributed to SLE. For SLE and non-SLE NP events, predicted annual, 5-, and 10-year direct costs and indirect costs were higher in new/ongoing versus no events. Direct costs were 1.5-fold higher and indirect costs 1.3-fold higher in new/ongoing versus no events. Indirect costs exceeded direct costs 3.0 to 5.2 fold. Among frequent SLE NP events, new/ongoing seizure disorder and cerebrovascular disease accounted for the largest increases in annual direct costs. For non-SLE NP events, new/ongoing polyneuropathy accounted for the largest increase in annual direct costs, and new/ongoing headache and mood disorder for the largest increases in indirect costs. Conclusion: Patients with new/ongoing SLE or non-SLE NP events incurred higher direct and indirect costs.

Published
2023

128. Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome

Author

Harris, Valerie M., Sharma, Rohan, Cavett, Joshua, Kurien, Biji T., Liu, Ke, Koelsch, Kristi A., Rasmussen, Astrid, Radfar, Lida, Lewis, David, Stone, Donald U., Kaufman, C. Erick, Li, Shibo, Segal, Barbara, Wallace, Daniel J., Weisman, Michael H., Venuturupalli, Swamy, Kelly, Jennifer A., Alarcon-Riquelme, Marta E., Pons-Estel, Bernardo, Jonsson, Roland, Lu, Xianglan, Gottenberg, Jacques-Eric, Anaya, Juan-Manuel, Cunninghame-Graham, Deborah S., Huang, Andrew J.W., Brennan, Michael T., Hughes, Pamela, Alevizos, Ilias, Miceli-Richard, Corinne, Keystone, Edward C., Bykerk, Vivian P., Hirschfield, Gideon, Xie, Gang, Ng, Wan-Fai, Nordmark, Gunnel, Bucher, Sara Magnusson, Eriksson, Per, Omdal, Roald, Rhodus, Nelson L., Rischmueller, Maureen, Rohrer, Michael, Wahren-Herlenius, Marie, Witte, Torsten, Mariette, Xavier, Lessard, Christopher J., Harley, John B., Sivils, Kathy L., and Scofield, R. Hal

Published
2016
Full Text
View/download PDF

133. Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics (SLICC) Cohort using Multistate Modelling

Author

Clarke, Ann E., primary, Hanly, John G., additional, Urowitz, Murray B., additional, St. Pierre, Yvan, additional, Gordon, Caroline, additional, Bae, Sang‐Cheol, additional, Romero‐Diaz, Juanita, additional, Sanchez‐Guerrero, Jorge, additional, Bernatsky, Sasha, additional, Wallace, Daniel J., additional, Isenberg, David A., additional, Rahman, Anisur, additional, Merrill, Joan T., additional, Fortin, Paul R., additional, Gladman, Dafna D., additional, Bruce, Ian N., additional, Petri, Michelle, additional, Ginzler, Ellen M., additional, Dooley, Mary Anne, additional, Ramsey‐Goldman, Rosalind, additional, Manzi, Susan, additional, Jönsen, Andreas, additional, Alarcón, Graciela S., additional, Van Vollenhoven, Ronald F., additional, Aranow, Cynthia, additional, Mackay, Meggan, additional, Ruiz‐Irastorza, Guillermo, additional, Lim, S. Sam, additional, Inanc, Murat, additional, Kalunian, Kenneth C., additional, Jacobsen, Soren, additional, Peschken, Christine A., additional, Kamen, Diane L., additional, Askanase, Anca, additional, and Farewell, Vernon, additional

Published
2023
Full Text
View/download PDF

134. Rejection slips: on not getting into the New Yorker

Author

Wallace, Daniel

Subjects
Literature/writing
Abstract

MY FIRST time? November 29, 1984. It was the third story I'd ever written and, like the other two, was brooding and mannered and obscure, the work of a young [...]

Published
2017

138. Evaluating the Construct of Damage in Systemic Lupus Erythematosus

Author

Johnson, Sindhu R., primary, Gladman, Dafna D., additional, Brunner, Hermine I., additional, Isenberg, David, additional, Clarke, Ann E., additional, Barber, Megan R. W., additional, Arnaud, Laurent, additional, Fortin, Paul R., additional, Mosca, Marta, additional, Voskuyl, Alexandre E., additional, Manzi, Susan, additional, Aranow, Cynthia, additional, Askanase, Anca, additional, Alarcón, Graciela S., additional, Bae, Sang‐Cheol, additional, Costedoat‐Chalumeau, Nathalie, additional, English, Jessica A., additional, Pons‐Estel, Guillermo J., additional, Pons‐Estel, Bernardo A., additional, Gilman, Rebecca, additional, Ginzler, Ellen M., additional, Hanly, John G., additional, Jacobsen, Soren, additional, Kalunian, Kenneth, additional, Kamen, Diane L., additional, Lambalgen, Chynace, additional, Legge, Alexandra, additional, Lim, S. Sam, additional, Mak, Anselm, additional, Morand, Eric F., additional, Peschken, Christine A., additional, Petri, Michelle, additional, Rahman, Anisur, additional, Ramsey‐Goldman, Rosalind, additional, Reynolds, John A., additional, Romero‐Diaz, Juanita, additional, Ruiz‐Irastorza, Guillermo, additional, Sanchez‐Guerrero, Jorge, additional, Svenungsson, Elisabet, additional, Touma, Zahi, additional, Urowitz, Murray, additional, Vinet, Evelyne, additional, van Vollenhoven, Ronald F., additional, Waldhauser, Heather, additional, Wallace, Daniel J., additional, Zoma, Asad, additional, and Bruce, Ian N., additional

Published
2022
Full Text
View/download PDF

139. Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II , Randomized, Double‐Blind , Placebo‐Controlled Dose‐Ranging Trial

Author

Wallace, Daniel J., primary, Dörner, Thomas, additional, Pisetsky, David S., additional, Sanchez‐Guerrero, Jorge, additional, Patel, Anand C., additional, Parsons‐Rich, Dana, additional, Le Bolay, Claire, additional, Drouin, Elise E., additional, Kao, Amy H., additional, Guehring, Hans, additional, and Dall'Era, Maria, additional

Published
2022
Full Text
View/download PDF

141. A 5-Year Retrospective, Observational Study Assessing Rheumatoid Arthritis Disease Outcome Measures to Characterize Systemic Lupus Erythematosus Burden in the USA

Author

Bell, Christopher F., primary, Huang, Shirley P., additional, Yu, Louise H., additional, DerSarkissian, Maral, additional, Germain, Guillaume, additional, Concoff, Andrew L., additional, Averell, Carlyne M., additional, Rubin, Bernard, additional, Gu, Yuqian M., additional, Duh, Mei Sheng, additional, and Wallace, Daniel J., additional

Published
2022
Full Text
View/download PDF

142. 103 Exploratory segregation of patients upon their levels of anti- mitochondrial antibodies (AMAs) reveals associations between AMAs and disease manifestations

Author

Becker, Yann LC, primary, Boilard, Éric, additional, Rollet-Labelle, Emmanuelle, additional, Lood, Christian, additional, Julien, Anne-Sophie, additional, Leclerc, Joannie, additional, Lévesque, Tania, additional, Urowitz, Murray, additional, Hanly, John, additional, Gordon, Caroline, additional, Bae, Sang-Cheol, additional, Romero-Diaz, Juanita, additional, Sanchez-Guerrero, Jorge, additional, Clarke, Ann E, additional, Bernatsky, Sasha, additional, Wallace, Daniel, additional, Isenberg, David, additional, Rahman, Anisur, additional, Merrill, Joan, additional, Gladman, Dafna, additional, Bruce, Ian N, additional, Petri, Michelle, additional, Ginzler, Ellen, additional, Dooley, Mary Anne, additional, Ramsey-Goldman, Rosalind, additional, Manzi, Susan, additional, Jönsen, Andreas, additional, Alarcon, Graciela, additional, Vollenhoven, Ronald van, additional, Aranow, Cynthia, additional, Ruiz-Irastorza, Guillermo, additional, Lim, Sam, additional, Inanc, Murat, additional, Kalunian, Kenneth, additional, Jacobsen, Soren, additional, Peschken, Christine, additional, Kamen, Diane, additional, Askanase, Anca, additional, Buyon, Jill, additional, and Fortin, Paul R, additional

Published
2022
Full Text
View/download PDF

143. 102 M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort

Author

Krustev, Eugene, primary, Hanly, John G, additional, Chin, Ricky, additional, Buhler, Katherine, additional, Cardwell, Francesca, additional, Urowitz, Murray B, additional, Gordon, Caroline, additional, Bae, Sang-Cheol, additional, Romero-Diaz, Juanita, additional, Sanchez-Guerrero, Jorge, additional, Bernatsky, Sasha, additional, Wallace, Daniel J, additional, Isenberg, David A, additional, Rahman, Anisur, additional, Merrill, Joan T, additional, Fortin, Paul R, additional, Gladman, Dafna D, additional, Bruce, Ian N, additional, Petri, Michelle, additional, Ginzler, Ellen M, additional, Dooley, Mary Anne, additional, Ramsey-Goldman, Rosalind, additional, Manzi, Susan, additional, Jönsen, Andreas, additional, Alarcón, Graciela S, additional, Vollenhoven, Ronald F van, additional, Aranow, Cynthia, additional, Mackay, Meggan, additional, Ruiz-Irastorza, Guillermo, additional, Lim, Sam, additional, Inanc, Murat, additional, Kalunian, Kenneth C, additional, Jacobsen, Søren, additional, Peschken, Christine A, additional, Kamen, Diane L, additional, Askanase, Anca, additional, Buyon, Jill, additional, Fritzler, Marvin J, additional, Clarke, Ann E, additional, and Choi, May Y, additional

Published
2022
Full Text
View/download PDF

144. 2001 α-ketoglutarate-dependent KDM6 histone demethylases epigenetically regulate Interferon Stimulated Gene expression in Lupus

Author

Montano, Erica N, primary, Bose, Moumita, additional, Huo, Lihong, additional, Tumurkhuu, Gantsetseg, additional, Santos, Gabriela De Los, additional, Stotland, Aleksandr B, additional, Wei, Janet, additional, Bairey Merz, C Noel, additional, Martins, Gislaine, additional, Lalani, Sarfaraz, additional, Lawrenson, Kate, additional, Parker, Sarah, additional, Ishimori, Mariko, additional, Wallace, Daniel J, additional, and Jefferies, Caroline, additional

Published
2022
Full Text
View/download PDF

146. 603 Remission and low disease activity are associated with lower health care costs in an international inception cohort of patients with systemic lupus erythematosus

Author

Clarke, Ann E, primary, Ugarte-Gil, Manuel Francisco, additional, Barber, Megan RW, additional, Hanly, John G, additional, Urowitz, Murray B, additional, Pierre, Yvan St, additional, Gordon, Caroline, additional, Bae, Sang-Cheol, additional, Romero-Diaz, Juanita, additional, Sanchez-Guerrero, Jorge, additional, Bernatsky, Sasha, additional, Wallace, Daniel J, additional, Isenberg, David A, additional, Rahman, Anisur, additional, Merrill, Joan T, additional, Fortin, Paul R, additional, Gladman, Dafna D, additional, Bruce, Ian N, additional, Petri, Michelle, additional, Ginzler, Ellen M, additional, Dooley, Mary Anne, additional, Ramsey-Goldman, Rosalind, additional, Manzi, Susan, additional, Jönsen, Andreas, additional, Vollenhoven, Ronald FVan, additional, Aranow, Cynthia, additional, Mackay, Meggan, additional, Ruiz-Irastorza, Guillermo, additional, Sam Lim, S, additional, Inanc, Murat, additional, Kalunian, Kenneth C, additional, Jacobsen, Soren, additional, Peschken, Christine A, additional, Kamen, Diane L, additional, Askanase, Anca, additional, Pons-Estel, Bernardo A, additional, and Alarcón, Graciela S, additional

Published
2022
Full Text
View/download PDF

147. Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

Author

Montalban, Xavier, primary, Wallace, Daniel, additional, Genovese, Mark C, additional, Tomic, Davorka, additional, Parsons-Rich, Dana, additional, Le Bolay, Claire, additional, Kao, Amy H, additional, and Guehring, Hans, additional

Published
2022
Full Text
View/download PDF

149. Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic

Author

Cardwell, Francesca S, primary, Elliott, Susan J, additional, Chin, Ricky, additional, St Pierre, Yvan, additional, Choi, May Y, additional, Urowitz, Murray B, additional, Ruiz-Irastorza, Guillermo, additional, Bernatsky, Sasha, additional, Wallace, Daniel J, additional, Petri, Michelle A, additional, Manzi, Susan, additional, Bae, Sang-Cheol, additional, Shin, Jung-Min, additional, Mak, Anselm, additional, Cho, Jiacai, additional, Peschken, Christine A, additional, Ramsey-Goldman, Rosalind, additional, Fortin, Paul R, additional, Hanly, John G, additional, Pons-Estel, Bernardo A, additional, Nieto, Romina, additional, Askanase, Anca D, additional, Romero-Diaz, Juanita, additional, Mosca, Marta, additional, Bruce, Ian N, additional, Rowbottom, Leigha, additional, Mielczarek, Leanne, additional, Tse, Karin, additional, Marion, Ashley, additional, Cáhiz-González, Juan Carlos, additional, Cattoni, Teresa G, additional, Cornet, Alain, additional, and Clarke, Ann Elaine, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results